Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Author

D. Planchard

h-index 84 View on Semantic Scholar

We have 3 of 835 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Sep 2026

Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

BACKGROUND For patients with resected, ALK-positive non-small-cell lung cancer (NSCLC), adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in the global, phase 3, open-label, randomised ALINA trial. We report safety and health-related quality-of-life (HRQoL) outcomes from...

R. Dziadziuszko, J. S. Ahn, F. Barlesi et al. · 0 citations
Review Sep 2026

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.

Recent advances in NSCLC with established alterations are summarized, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and emerging targets are discussed, and emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency are discussed.

L. Hendriks, Jessica J. Lin, D. S. Tan et al. · 2 citations
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.